Home › NDC Lookup › RxCUI directory › RxCUI 2684851

Mycophenolate mofetil 200 MG/ML Oral Suspension [Myhibbin] — RxCUI 2684851

Name: Mycophenolate mofetil 200 MG/ML Oral Suspension [Myhibbin] (RxCUI 2684851)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic branded drug

RxCUI 2684851 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2684851

Official nameMycophenolate mofetil 200 MG/ML Oral Suspension [Myhibbin]

Concept typeSemantic branded drug (SBD)

RxNorm statusCurrent RxNorm concept

Also known asMyhibbin 200 MG/ML Oral Suspension; Myhibbin 200 MG in 1 mL Oral Suspension; Myhibbin 200 MG per 1 ML Oral Suspension

FDA products mapped1

Package NDCs mapped1

Reported Medicaid activity (SDUD)482 prescriptions · 3 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Mycophenolate Mofetil: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

It helps keep your body from rejecting a transplanted kidney, heart or liver. You take it together with other immunosuppressant medicines. It works by calming the immune cells that...
It's usually taken twice a day, by mouth as a capsule, tablet or liquid, or through an IV in the hospital. Follow your prescriber's directions and your label. Don't switch it with...
Diarrhea, nausea, vomiting and stomach pain are common. Call your doctor if you have a fever, chills or other signs of infection, unusual bruising or bleeding, black stools, severe...
What side effects are normal, and when should I call?

📖 Read our full Mycophenolate Mofetil guide →

🕸️ Concept Web — How Mycophenolate mofetil 200 MG/ML Oral Suspension... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept Mycophenolate mofetil 200 MG/ML Oral Suspension [Myhibbin] RxCUI 2684851 Semantic branded drug · SBD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 1

The active substance itself — no strength, form, or brand attached yet.
- Mycophenolate mofetil 68149 IN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Myhibbin 2684846 BN
Dose forms 9

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Mycophenolate mofetil Oral Suspension 374670 SCDF
- Mycophenolate mofetil Oral Liquid Product 1157870 SCDG
- Mycophenolate mofetil Oral Product 1157871 SCDG
- Mycophenolate mofetil Oral Suspension [Myhibbin] 2684850 SBDF
- Myhibbin Oral Liquid Product 2684849 SBDG
- Myhibbin Oral Product 2684848 SBDG
- Oral Suspension 316969 DF
- Oral Liquid Product 1151137 DFG
- +1 more in this family
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Mycophenolate mofetil 200 MG/ML Oral Suspension 311880 SCD
- Mycophenolate mofetil 200 MG/ML 331587 SCDC
- Mycophenolate mofetil 200 MG/ML [Myhibbin] 2684847 SBDC

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Mycophenolate mofetil 200 MG/ML Oral Suspension SCD · 311880
Mycophenolate mofetil 200 MG/ML SCDC · 331587
Mycophenolate mofetil Oral Suspension SCDF · 374670
Mycophenolate mofetil Oral Liquid Product SCDG · 1157870
Mycophenolate mofetil Oral Product SCDG · 1157871

Brand-Name Concepts

Mycophenolate mofetil 200 MG/ML [Myhibbin] SBDC · 2684847
Mycophenolate mofetil Oral Suspension [Myhibbin] SBDF · 2684850
Myhibbin Oral Liquid Product SBDG · 2684849
Myhibbin Oral Product SBDG · 2684848
Myhibbin BN · 2684846

📦 FDA Products & Package NDCs

1 product · 1 package NDC

1 package NDC map to RxCUI 2684851 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
24338-0018-01	1 BOTTLE, PLASTIC in 1 CARTON (24338-018-01) / 175 mL in 1...	MYHIBBIN	Azurity Pharmaceuticals, Inc.	2024-06-10

Observed labelers: Azurity Pharmaceuticals, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.

Code	Descriptor	Mapped packages	Sources
J7514	Mycophenol (myhibbin) 100 mg	1	CMS

⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.